Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

NASDAQ:TNXP - Nasdaq - US8902608392 - Common Stock - Currency: USD

15.71  -0.15 (-0.95%)

After market: 15.61 -0.1 (-0.64%)

Fundamental Rating

2

TNXP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. TNXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TNXP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNXP has reported negative net income.
TNXP had a negative operating cash flow in the past year.
In the past 5 years TNXP always reported negative net income.
TNXP had a negative operating cash flow in each of the past 5 years.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

TNXP's Return On Assets of -79.83% is on the low side compared to the rest of the industry. TNXP is outperformed by 69.01% of its industry peers.
TNXP has a Return On Equity of -93.18%. This is comparable to the rest of the industry: TNXP outperforms 47.89% of its industry peers.
Industry RankSector Rank
ROA -79.83%
ROE -93.18%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

TNXP's Gross Margin of 23.07% is fine compared to the rest of the industry. TNXP outperforms 72.54% of its industry peers.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNXP has more shares outstanding
Compared to 5 years ago, TNXP has more shares outstanding
Compared to 1 year ago, TNXP has an improved debt to assets ratio.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

TNXP has an Altman-Z score of -4.27. This is a bad value and indicates that TNXP is not financially healthy and even has some risk of bankruptcy.
TNXP has a Altman-Z score of -4.27. This is comparable to the rest of the industry: TNXP outperforms 44.01% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that TNXP is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.03, TNXP is not doing good in the industry: 60.56% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -4.27
ROIC/WACCN/A
WACC10.77%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.50 indicates that TNXP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.50, TNXP is in the better half of the industry, outperforming 66.55% of the companies in the same industry.
TNXP has a Quick Ratio of 6.04. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
TNXP has a better Quick ratio (6.04) than 64.61% of its industry peers.
Industry RankSector Rank
Current Ratio 6.5
Quick Ratio 6.04
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

TNXP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -612.92%.
TNXP shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.93%.
EPS 1Y (TTM)-612.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.5%
Revenue 1Y (TTM)29.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-31.68%

3.2 Future

The Earnings Per Share is expected to grow by 41.25% on average over the next years. This is a very strong growth
TNXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.28% yearly.
EPS Next Y27.45%
EPS Next 2Y41.25%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.21%
Revenue Next 2Y179.39%
Revenue Next 3Y118.28%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -500M -1B -1.5B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNXP. In the last year negative earnings were reported.
Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K

4.3 Compensation for Growth

A more expensive valuation may be justified as TNXP's earnings are expected to grow with 41.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.25%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (4/17/2025, 8:00:00 PM)

After market: 15.61 -0.1 (-0.64%)

15.71

-0.15 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners3.07%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap108.08M
Analysts82.86
Price Target595 (3687.4%)
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)94.92%
Min EPS beat(2)92.31%
Max EPS beat(2)97.53%
EPS beat(4)3
Avg EPS beat(4)-58.22%
Min EPS beat(4)-477.45%
Max EPS beat(4)97.53%
EPS beat(8)5
Avg EPS beat(8)-25.63%
EPS beat(12)8
Avg EPS beat(12)-10.25%
EPS beat(16)9
Avg EPS beat(16)-8.61%
Revenue beat(2)0
Avg Revenue beat(2)-18.97%
Min Revenue beat(2)-27.68%
Max Revenue beat(2)-10.27%
Revenue beat(4)0
Avg Revenue beat(4)-28.02%
Min Revenue beat(4)-38.15%
Max Revenue beat(4)-10.27%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9900.05%
EPS NQ rev (1m)99.5%
EPS NQ rev (3m)40.63%
EPS NY rev (1m)38.05%
EPS NY rev (3m)-6094.93%
Revenue NQ rev (1m)-39.29%
Revenue NQ rev (3m)-37.8%
Revenue NY rev (1m)-39.07%
Revenue NY rev (3m)-28.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.71
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1966.53
EYN/A
EPS(NY)-1426.79
Fwd EYN/A
FCF(TTM)-8.87
FCFYN/A
OCF(TTM)-8.86
OCFYN/A
SpS1.47
BVpS20.28
TBVpS20.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.83%
ROE -93.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.07%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.51%
Cap/Sales 1.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.5
Quick Ratio 6.04
Altman-Z -4.27
F-Score4
WACC10.77%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-612.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.5%
EPS Next Y27.45%
EPS Next 2Y41.25%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)29.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-31.68%
Revenue Next Year-12.21%
Revenue Next 2Y179.39%
Revenue Next 3Y118.28%
Revenue Next 5YN/A
EBIT growth 1Y34.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.27%
OCF growth 3YN/A
OCF growth 5YN/A